<![CDATA[Sequencing Beyond Frontline: Resistance, Later-Line Options, and Emerging Directions in EGFR-Mutant NSCLC]]>

Summary

Editorial content discussing treatment sequencing strategies in EGFR-mutant non-small cell lung cancer, addressing how first-line therapy selection impacts later-line options and disease progression management.